These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 13574395)

  • 1. [Lanthasol aerosol in the treatment of obliterating peripheral arterial diseases and in coronary disease].
    NARDI FL
    Gazz Med Ital; 1958 Aug; 117(8):333-9. PubMed ID: 13574395
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic activity of cyclospasmol (3,5,5-trimethylcyclohexanol mandelic ester) in coronary & peripheral vascular diseases; casuistic contribution].
    BALLERINI C; FIORE G
    Gazz Med Ital; 1959 Apr; 118(4):136-41. PubMed ID: 13664047
    [No Abstract]   [Full Text] [Related]  

  • 3. Experiences in treating coronary and peripheral vascular diseases.
    FRIEDLANDER HS
    N Y State J Med; 1954 Dec; 54(24):3396-400. PubMed ID: 13214457
    [No Abstract]   [Full Text] [Related]  

  • 4. [The biological and therapeutic action of Triparanol].
    RAVINA A
    Presse Med (1893); 1960 Oct; 68():1700-1. PubMed ID: 13739904
    [No Abstract]   [Full Text] [Related]  

  • 5. [Further practical study of lanthasol therapy of coronary disease].
    NARDI FL
    Gazz Med Ital; 1958 Oct; 117(10):429-31. PubMed ID: 13626211
    [No Abstract]   [Full Text] [Related]  

  • 6. [Vasodilator treatment with a derivative of beta-phenylethylamine. Results in 5 cases of arterial syndromes].
    DULAC JF; MANY P; PICARD P
    Presse Med (1893); 1959 Sep; 67():1546-7. PubMed ID: 13818551
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intra-arterial curare therapy of peripheral obliterating arteriopathy].
    ENRIA G
    Minerva Cardioangiol; 1957 Oct; 5(10):461-3. PubMed ID: 13503741
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene therapy for arterial disease: is it hype or is there hope? New and promising treatments were on the map several years ago, but clinical applications so far have proven elusive.
    Heart Advis; 2007 Apr; 10(4):9. PubMed ID: 17494203
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lytic cocktail in the treatment of juvenile chronic obliterating arterial disease].
    NICOLOSI G
    Minerva Med; 1953 Sep; 44(70):497-9. PubMed ID: 13110893
    [No Abstract]   [Full Text] [Related]  

  • 10. Concomitant peripheral arterial disease and coronary artery disease: therapeutic opportunities.
    Bittl JA; Hirsch AT
    Circulation; 2004 Jun; 109(25):3136-44. PubMed ID: 15226231
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronary and peripheral interventions: an update.
    Lüscher TF
    Eur Heart J; 2016 Apr; 37(14):1085-7. PubMed ID: 27056341
    [No Abstract]   [Full Text] [Related]  

  • 12. [Indications, limits and future of epidural spinal cord electrical stimulation for coronary and peripheral artery disease].
    Gersbach P; Gardaz JP; Ferrari E; Haesler E; von Segesser LK
    Rev Med Suisse; 2008 Mar; 4(150):797-804. PubMed ID: 18476650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [On the clinical use of inactivated kallikrein].
    WELKOBORSKY E
    Ther Ggw; 1960 May; 99():239-42. PubMed ID: 13843839
    [No Abstract]   [Full Text] [Related]  

  • 14. [Contribution to the study of a pyrimido-pyrimidine derivative].
    LOPEZ MERINO V; ALGARRA GONZALEZ F; PONS ESPANA E
    Med Esp; 1961 Sep; 46():204-13. PubMed ID: 14466606
    [No Abstract]   [Full Text] [Related]  

  • 15. Who should treat patients with peripheral arterial disease - the vascular specialist.
    Sillesen H
    Eur J Vasc Endovasc Surg; 2002 Jul; 24(1):1-3. PubMed ID: 12127841
    [No Abstract]   [Full Text] [Related]  

  • 16. [Preliminary results in the use of trypsin in the treatment of chronic peripheral obliterating arterial diseases].
    CONTI A; MAZZEO F
    Minerva Chir; 1957 May; 12(9):419-25. PubMed ID: 13451265
    [No Abstract]   [Full Text] [Related]  

  • 17. [Photoplethysmographic changes after lumbar gangliectomy in chronic peripheral obliterating arterial diseases].
    FABI M; MALAGU I; FUSAROLIP ; RANERID
    Arcisp S Anna Ferrara; 1962; 15():409-24. PubMed ID: 13891187
    [No Abstract]   [Full Text] [Related]  

  • 18. [Studies on the effect of intra-arterial oxygen insufflation in patients with obliterating vascular diseases].
    HESS H; BARTELMESS R
    Medizinische; 1956 Mar; (11):374-8. PubMed ID: 13321425
    [No Abstract]   [Full Text] [Related]  

  • 19. [Bogomoletz serum in therapy of chronic peripheral obliterating arteriopathy].
    VERGANI G
    Gazz Med Ital; 1958 Jan; 117(1):4-5. PubMed ID: 13524597
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of a new drug with sympatholytic and analgesic action in therapy of chronic juvenile and arteriosclerotic peripheral obliterating arteriopathy].
    GUAGLIANO G; STOPPANI L
    Minerva Chir; 1958 Nov; 13(21):1282-6. PubMed ID: 13622298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.